UNSPSC 51334401: Mindoperone

This classification denotes an anxiolytic with the molecular formula C25H29FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 556OP2G5M2, chemically known as butyrophenone, 4-fluoro-4-(4-(6-methoxy-2-methylindol-3-yl)piperidino)- but generally known as mindoperone, which bears US NIH Compound Identifier 172296. European Medicines Agency schedules Mindoperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08977MIG.

UNSPSC 51334401 Mindoperone is a Commodity code that covers pharmaceutical products—specifically opioid antagonists, drug deactivation compounds, and generic multi-source pharmaceuticals—that state and local health agencies, departments of human services, and cooperative purchasing alliances procure for community health programs, emergency response, and institutional pharmacy supply. State and local governments buy these products through competitive bidding (IFB), requests for proposals (RFP), and cooperative purchasing mechanisms to support overdose prevention, harm reduction, and routine pharmaceutical distribution across health departments, county health buildings, and multi-state consortiums. Issuing bodies include county health departments, state health and human services commissions, and regional cooperative purchasing alliances that aggregate demand across multiple jurisdictions and authorized wholesale channels. Recent solicitations reflect a mix of single-jurisdiction direct procurement and multi-state cooperative contracting, with vendors required to demonstrate FDA compliance, Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) adherence, and established relationships with authorized pharmaceutical wholesalers.

Recent activity spans the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a due date of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and wholesale channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers across participating states including Oregon, with proposals due March 26, 2026. Vendors must maintain commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and accept a 3 percent administrative fee on all contract purchases under the MMCAP agreement.